DarioHealth Unveils its Digital Musculoskeletal Solution Dario Move at HLTH 2021
- New Product Significantly Expands Impact and Value of Dario's Integrated Digital Therapeutics Platform
- Full Integration Just Nine Months Following the Acquisition of Upright Technologies Represents Achievement of a Significant Company Milestone
- Musculoskeletal Problems are Considered Among the Costliest for Employers and Health Plans
Oct 18, 2021
BOSTON, Oct. 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of Dario Move, a new digital physical therapy solution to manage common musculoskeletal (MSK) conditions that drive significant costs for employers and health plans. The solution is being unveiled at HLTH 2021, one of the largest and most important conferences for health innovation, which is taking place in a hybrid format (in-person and virtual) from October 17-20 in Boston.
"The launch of Dario Move marks a significant achievement for our Company, as we successfully and efficiently integrated the Upright MSK solution into our comprehensive multi-chronic condition digital therapeutics platform, further expanding its industry-leading breadth and reach," said Erez Raphael, CEO and President, DarioHealth. "Dario Move is the realization of our vision for multi-use applications of the sensor technologies acquired during our purchase of Upright, and this new solution unlocks vast new market potential. Further, we believe that the integration with our multi-chronic platform strengthens our platform from a buyer perspective and in our ability to deliver results and value for our partners."
With the addition of Dario Move, Dario's full suite is now positioned to support comprehensive chronic condition management across three of the top priorities for employers: diabetes, behavioral health and metabolic health needs.
The cost of care for musculoskeletal health has increased significantly during the last decade, making it one of the costliest conditions for employers today, according to a recent survey of large employers.1 Yet even though 50% of U.S. adults are affected by an MSK disorder, many people who would benefit from traditionally lower-cost treatments such as physical therapy do not ever access care.2,3 Dario Move's digital physical therapy creates a better way to improve access by shifting the site of care to each person's home, providing easy to use sensors and individualized exercises; all powered by Dario's behavior change platform. Digital physical therapy provides for more cost-effective, assessable and sustainable engagement.
Dario Move makes it easy for people to improve their musculoskeletal health by combining intelligent software, technology and professional human support, including:
- A single biofeedback sensor for ease of use;
- Personalized, evidence-based exercise programs designed by physical therapists for effective treatment;
- Real-time feedback to help improve movement;
- Real-time support from coaches and Physical Therapists throughout treatment to monitor, adjust and encourage progress; and
- A highly personalized experience across Dario's full suite of chronic conditions solutions.
"Dario Move offers an attractive alternative to more traditional and complex solutions by providing engaging and effective digital treatments in a member's home," said Rick Anderson, President and General Manager North America. "This increases the likelihood of member engagement and retention to care which improves clinical outcomes and lowers the cost of care. Integration across our suite of products allows us to provide an integrated, personalized user experience on a single platform while providing operational efficiencies that our clients want."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market - covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.
Dario's next-generation, AI-powered, digital therapeutic platform supports more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.
Dario's unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.
The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users' health.
On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it states that Dario Move significantly expands the impact and value of its digital therapeutics platform, that the integration with its multi-chronic platform strengthens its platform from a buyer perspective and in its ability to deliver results and value for its partners and the benefits to be realized by users from the Dario Move platform. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
SOURCE DarioHealth Corp.